Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 9/20 | 0.51 |
| ▸ | TCF7L2 | Q9NQB0 | 9/20 | 0.51 |
| ▸ | HTR1A | P08908 | 4/20 | 0.47 |
| ▸ | HTR1B | P28222 | 4/20 | 0.47 |
| ▸ | HTR1D | P28221 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HTR1F | P30939 | 3/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5025434 | 1.00 | CTNNB1 (0.51) | CTNNB1TCF7L2HTR1AHTR1BHTR1D | |
| SCHEMBL5028536 | 0.91 | CTNNB1 (0.63) | CTNNB1TCF7L2HTR1AHTR1BHTR1D | |
| SCHEMBL5028530 | 0.91 | CTNNB1 (0.63) | CTNNB1TCF7L2HTR1AHTR1BHTR1D | |
| Hydrochloric Acid SCHEMBL5028655 | 0.90 | CTNNB1 (0.62) | CTNNB1TCF7L2HTR1AHTR1BHTR1D | |
| Hydrochloric Acid SCHEMBL5028652 | 0.90 | CTNNB1 (0.62) | CTNNB1TCF7L2HTR1AHTR1BHTR1D | |
| SCHEMBL5022830 | 0.89 | MLLT1 (0.44) | CTNNB1TCF7L2MAPTMCHR1 | |
| SCHEMBL5022834 | 0.89 | MLLT1 (0.44) | CTNNB1TCF7L2MAPTMCHR1 | |
| SCHEMBL27597773 | 0.86 | CTNNB1 (0.51) | CTNNB1TCF7L2HTR1AHTR1BHTR1D | |
| SCHEMBL5022650 | 0.85 | RAB9A (0.46) | MAPTSMN1; SMN2 | |
| SCHEMBL5022654 | 0.85 | RAB9A (0.46) | MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474145-B1 | QUINOLINE DERIVATIVES AS NPY ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-04-23 | — | — | EP | disclosed |
| CN-1627945-A | Quinoline derivatives as NPY antagonists | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | CN | disclosed |
| EP-1474145-A1 | QUINOLINE DERIVATIVES AS NPY ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| US-6696467-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030153553-A1 | Quinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | US | disclosed |
| WO-2003066055-A1 | QUINOLINE DERIVATIVES AS NPY ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153553-A1 | Quinoline derivatives | NPY1R, NPY4R, GLP1R | CTNNB1 4659/4885TCF7L2 1803/4885HTR1A 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.